|Keywords:||qPCR; mRNA; leukemia; western blot; β-actin; Medical and Health Sciences; Medical Biotechnology; Biomedical Laboratory Science/Technology; Medicin och hälsovetenskap; Medicinsk bioteknologi; Biomedicinsk laboratorievetenskap/teknologi; Biomedicinska analytikerprogrammet; Biomedicinska analytikerprogrammet|
|Full text PDF:||http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-202702|
Cancer remains one of the most common causes for death in the world today. Researchers are continuously trying to improve old, and develop new, methods in order to strife this global problem. Much research is being made trying to find new specific biomarkers that can be used to detect and diagnose cancer in an early stage. One candidate protein for possible future use as a biomarker is tripeptidyl-peptidase II (TPPII) which has previously been shown to be up-regulated in Burkitt´s lymphoma. This paper focuses on the expression of TPPII on an mRNA-level to see if there is any difference between expression in human leucocytes from patients with a leukemia diagnosis and a healthy volunteer, in order to evaluate if the expression of TPPII have any future use as a biomarker. Patient samples were analyzed using real time qPCR, to study the expression of mRNA, and Western blot, in order to correlate the mRNA findings with protein expression. Three different cell lines with different characteristics regarding expression and function of TPPII were also used to validate the methods used and for comparison with the patient samples analyzed. A difference in expression of mRNA were seen between the different patient samples, both individually and between larger groups of samples with the same diagnosis, indicating a large individual variation, thus making future use in a clinical setting difficult. However, seeing as only a few samples were analyzed in this study, more research must be done in order to draw any final conclusions.